Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
Fernando Bril, Kenneth Cusi
Diabetes Care (2017) Vol. 40, Iss. 3, pp. 419-430
Open Access | Times Cited: 312

Showing 26-50 of 312 citing articles:

The Effect of HBV Therapy on Glycemic Control in HBV‐Infected Patients With Diabetes: A 90‐day Multicenter Study
Qi Liu, Jie Huang, Jingyi Hu, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1
Nuciferine ameliorates hepatic steatosis in high‐fat diet/streptozocin‐induced diabetic mice through a PPARα/PPARγ coactivator‐1α pathway
Chao Zhang, Jianjun Deng, Dan Liu, et al.
British Journal of Pharmacology (2018) Vol. 175, Iss. 22, pp. 4218-4228
Open Access | Times Cited: 154
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Naveed Sattar, David Fitchett, Stefan Hantel, et al.
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2155-2163
Open Access | Times Cited: 143
Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism
Amin Ardestani, Blaž Lupše, Kathrin Maedler
Trends in Endocrinology and Metabolism (2018) Vol. 29, Iss. 7, pp. 492-509
Closed Access | Times Cited: 134
Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
Charng-Cherng Chyau, Hsueh‐Fang Wang, Wenjuan Zhang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 1, pp. 360-360
Open Access | Times Cited: 124
Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models
Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, et al.
EBioMedicine (2018) Vol. 31, pp. 122-132
Open Access | Times Cited: 121
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun‐Jung Rhee
Endocrinology and Metabolism (2019) Vol. 34, Iss. 3, pp. 226-226
Open Access | Times Cited: 88
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Alfredo Caturano, Carlo Acierno, Riccardo Nevola, et al.
Processes (2021) Vol. 9, Iss. 1, pp. 135-135
Open Access | Times Cited: 79
The metabolic basis of nonalcoholic steatohepatitis
Manu V. Chakravarthy, Brent A. Neuschwander‐Tetri
Endocrinology Diabetes & Metabolism (2020) Vol. 3, Iss. 4
Open Access | Times Cited: 78
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship
Cristina Muzîca, Cătălin Sfarti, Anca Trifan, et al.
Canadian Journal of Gastroenterology and Hepatology (2020) Vol. 2020, pp. 1-5
Open Access | Times Cited: 75
Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima, et al.
Journal of Diabetes Investigation (2020) Vol. 11, Iss. 6, pp. 1612-1622
Open Access | Times Cited: 72
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
Mohammed Eslam, Aijaz Ahmed, Jean‐Pierre Després, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 9, pp. 743-753
Open Access | Times Cited: 72
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Karolina Drożdż, Katarzyna Nabrdalik, Weronika Hajzler, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 71
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
Yumie Takeshita, Masao Honda, Kenichi Harada, et al.
Diabetes Care (2022) Vol. 45, Iss. 9, pp. 2064-2075
Open Access | Times Cited: 66
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
Jiyun Park, Gyuri Kim, Bongsung Kim, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 40
Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
Chenxu Ge, Jun Tan, Xianling Dai, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Nonalcoholic Fatty Liver Disease
Scott Isaacs
Endocrinology and Metabolism Clinics of North America (2022) Vol. 52, Iss. 1, pp. 149-164
Closed Access | Times Cited: 37
Diabetes and cirrhosis: Current concepts on diagnosis and management
Laurent Castéra, Kenneth Cusi
Hepatology (2023) Vol. 77, Iss. 6, pp. 2128-2146
Closed Access | Times Cited: 36
Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis
Fernando Bril, Arun J. Sanyal, Kenneth Cusi
Clinics in Liver Disease (2023) Vol. 27, Iss. 2, pp. 187-210
Closed Access | Times Cited: 34
Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial
Yu Chung Chooi, Qinze Arthur Zhang, Faidon Magkos, et al.
American Journal of Clinical Nutrition (2023) Vol. 119, Iss. 3, pp. 788-799
Open Access | Times Cited: 22
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
Yulino Castillo-Núñez, Paloma Almeda‐Valdés, Guillermo González-Gálvez, et al.
Current Diabetes Reports (2024) Vol. 24, Iss. 7, pp. 158-166
Closed Access | Times Cited: 7
Effects of resveratrol supplementation on liver fat content in overweight and insulin‐resistant subjects: A randomized, double‐blind, placebo‐controlled clinical trial
Kοnstantinos Kantartzis, Louise Fritsche, Maria Bombrich, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 7, pp. 1793-1797
Closed Access | Times Cited: 79
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
Fernando Bril, Michael J. McPhaul, Michael P. Caulfield, et al.
Journal of Investigative Medicine (2018) Vol. 67, Iss. 2, pp. 303-311
Open Access | Times Cited: 77
The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans
Andreas Peter, Markéta Kovářová, Harald Staiger, et al.
AJP Endocrinology and Metabolism (2017) Vol. 314, Iss. 3, pp. E266-E273
Open Access | Times Cited: 75
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
Kenneth Cusi, Naveed Sattar, L.E. García-Pérez, et al.
Diabetic Medicine (2018) Vol. 35, Iss. 10, pp. 1434-1439
Closed Access | Times Cited: 71

Scroll to top